February 10, 2009 - On Jan. 21, 2009, Irvin Lafferty, who suffered with severe blockage of his heart valve, became the first patient in Illinois to receive a prosthetic heart valve through a procedure known as transapical transcatheter aortic valve implantation, which combines catheterization technology and traditional surgery, allowing doctors to implant a new heart valve in place of Lafferty's diseased valve while his heart remained beating.
"Traditional open-heart surgery is a very safe and effective way to replace diseased heart valves, but for many patients bypass surgery is not a viable option," said Patrick M. McCarthy, M.D., Northwestern Memorial's chief of cardiothoracic surgery and co-director of its Bluhm Institute and a Heller-Sacks professor of surgery at Northwestern University's Feinberg School of Medicine. "By utilizing the percutaneous technique -- meaning surgery is not required -- we are able to greatly reduce risk for these patients. We see percutaneous valve repair as not only having a great impact upon how high-risk patients are treated, but in how heart valve disease is treated period, in the U.S. and around the world."
Dr. McCarthy is a co-principal investigator for the clinical trial that provided Lafferty's new heart valve, which is formally referred to as the Placement of AoRTic TraNscathetER Valve, or PARTNER.
"Balloon aortic valvuloplasty has been traditionally offered as a palliative therapy for patients who were not candidates for aortic valve surgery," said the hospital's director of the cardiac catheterization laboratory Charles J. Davidson, M.D., who is also a co-principal investigator for the trial and a professor of medicine at Northwestern University's Feinberg School of Medicine. "This particular technique is a more durable treatment than balloon valvuloplasty and is potentially a breakthrough for treating high-risk patients."
"Surgery becomes far too risky when patients are conditionally weak or frail," said Chris Malaisrie M.D., a Northwestern Memorial cardiac surgeon and member of the site team evaluating this new procedure. "The goal is to replace diseased valve at minimal risk to these patients--many of whom have very limited therapeutic options. Aortic valve replacement is one of few therapies offering both symptomatic relief and improved long-term survival."
During insertion, the artificial valve remains collapsed until it reaches its destination. It is then expanded and released in place of diseased aortic heart valves. The prosthesis is made of stainless steel and biological leaflets that help direct the flow of blood in the heart. It is permanent and integrates an expandable stent that holds the valve in its intended position. Northwestern Memorial utilizes both the transfemoral (through the groin) and transapical (through the ribs) approaches. Implantation occurs in a hybrid operating room suite that incorporates elements of both a traditional OR and catheterization laboratory.
Dr. McCarthy, the principal investigator for this study, is a consultant for Edwards Lifesciences (for valve repair, not the study device used in the PARTNER trial), the manufacturer of the investigational valve.
Participation in the PARTNER study will last a minimum of five years. For more information about the trial contact Kerry Madden, RN, at the Bluhm Institute's Clinical Trials Unit at (312) 695-1806 or [email protected].
For more information: www.nmh.org/
November 18, 2024 
